{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Lapuleucel-T",
  "nciThesaurus": {
    "casRegistry": "",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A cell-based vaccine targets tumors expressing the HER2/neu marker.  HER-2/neu is a growth factor receptor, and its overexpression has been associated with a number of cancers including breast, ovarian, colon and lung cancers.  APC8024 comprise of autologous antigen-presenting peripheral blood mononuclear cells (APCs) that have been exposed to HER2/neu protein and can be administered to the patient.  These cells may stimulate an antitumor T-cell response to cancer cells expressing HER2/neu.",
    "fdaUniiCode": "J5Z87L8ROA",
    "identifier": "C2057",
    "preferredName": "Lapuleucel-T",
    "semanticType": "Immunologic Factor",
    "subclassOf": [
      "C1987"
    ],
    "synonyms": [
      "APC 8024",
      "APC8024",
      "DN24-02",
      "LAPULEUCEL-T",
      "Lapuleucel-T",
      "Neuvenge"
    ]
  }
}